Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Emergent BioSolutions Inc. publishes a filing, an earnings call transcript or a press release.

Get EBS alerts

About Atul Saran

Emergent BioSolutions Inc. reported in an 8-K filed March 23, 2023 that Atul Saran was terminated as Executive Vice President, Chief Strategy and Development Officer, effective March 17, 2023. Emergent BioSolutions Inc. reported in an 8-K filed January 9, 2023 that Atul Saran resigned as EVP and Chief Strategy and Development Officer, effective March 17, 2023. Emergent BioSolutions Inc. reported in an 8-K filed February 22, 2022 that Atul Saran was appointed Executive Vice President, Chief Strategy and Development Officer, effective March 1, 2022. The proxy statement of Emergent BioSolutions Inc. reports total compensation of $3,504,868 for Atul Saran in fiscal 2022, including a base salary of $574,846. Disclosed compensation is on record for 6 fiscal years. Atul Saran has spoken on 2 earnings calls across 1 company, most recently for Emergent BioSolutions Inc. on February 21, 2019. Emergent BioSolutions Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Emergent BioSolutions Inc. includes Daniel J. Abdun-Nabi (CEO, COO and Board Member), Joseph C. Papa (CEO and Board Member), Joseph Papa (CEO and Board Member) and 7 others.

“On March 17, 2023, in connection with the elimination of his position as Chief Strategy and Development Officer, the Company entered into a Separation Agreement (the "Separation Agreement") with Atul Saran.”
Emergent BioSolutions Inc. Form 8-K, filed March 23, 2023 · Read the filing
“Departure of Atul Saran, EVP and Chief Strategy and Development Officer, effective March 17.”
Emergent BioSolutions Inc. Form 8-K, filed January 9, 2023 · Read the filing

Atul Saran on recent calls

“You are correct the 30-month stay is coming up at the end of March, and we are anticipating a trial sometime later this year. The trial date has not been set, and we've had discussions with the judge in the court, but we don't have the exact timing on the scheduling yet.”
General Counsel, Emergent BioSolutions Inc. Q4 FY2018 Earnings Call ·
“There are patents that have been issued that are protecting the NARCAN Nasal Spray. It's something that we evaluated closely during the course of the acquisition process and came away with a strong comfort level that it will continue to help protect the NARCAN Nasal Spray as a branded product in the marketplace.”
General Counsel, Emergent BioSolutions Inc. Q3 FY2018 Earnings Call ·

Affiliation history

Company network

Leadership on record at Emergent BioSolutions Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Emergent BioSolutions Inc. (EBS) $574,846 $3,504,868
2021 Emergent BioSolutions Inc. (EBS) $553,885 $2,070,344
2020 Emergent BioSolutions Inc. (EBS) $528,803 $2,159,032
2019 Emergent BioSolutions Inc. (EBS) $503,774 $1,862,979
2018 Emergent BioSolutions Inc. (EBS) $488,730 $1,698,027
2017 Emergent BioSolutions Inc. (EBS) $283,179 $1,220,554

Recent activity